Corcept Therapeutics Incorporated (0I3Q.L)
USD 55.58
(-0.47%)
USD 55.58
(-0.47%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 127.03 Million | 120.32 Million | 167.89 Million | 151.97 Million | 136.11 Million | 115.66 Million |
| Net Income | 106.14 Million | 101.41 Million | 112.51 Million | 106.01 Million | 94.18 Million | 75.41 Million |
| Depreciation & Amortization | 2.36 Million | 2.96 Million | 3.06 Million | 2.23 Million | 2.17 Million | 236 Thousand |
| Deferred income taxes | -29.49 Million | -33.9 Million | 4.34 Million | 14.08 Million | 16.87 Million | 14.06 Million |
| Stock-based compensation | 48.94 Million | 42.44 Million | 42.93 Million | 33.53 Million | 29.31 Million | 23.74 Million |
| Change in working capital | 8.21 Million | 6.01 Million | -57 Thousand | -5.35 Million | -4.68 Million | 3.92 Million |
| Other non-cash items | -9.12 Million | 1.38 Million | 5.09 Million | 1.45 Million | -1.73 Million | -1.72 Million |
| Investing Cash Flow | 90.9 Million | -114.32 Million | 136.12 Million | -119.26 Million | -117.82 Million | -90.76 Million |
| Investments in PPE | -139 Thousand | -413 Thousand | -469 Thousand | -1.23 Million | -1.08 Million | -298 Thousand |
| Acquisitions | -91.04 Million | 113.91 Million | -136.59 Million | 118.02 Million | 116.74 Million | - |
| Investment purchases | -328.74 Million | -355.06 Million | -312.8 Million | -420.11 Million | -299.03 Million | -233.12 Million |
| Sales/Maturities of investments | 419.79 Million | 241.15 Million | 449.4 Million | 302.08 Million | 182.29 Million | 142.65 Million |
| Other Investing Activities | 91.04 Million | -113.91 Million | 136.59 Million | -118.02 Million | -116.74 Million | -90.46 Million |
| Financing Cash Flow | -148.72 Million | -17.28 Million | -302.59 Million | 12.21 Million | -28.64 Million | -14.33 Million |
| Debt repayment | - | -2.19 Million | -2.02 Million | -1.68 Million | -1.45 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -145.42 Million | -21.66 Million | -295.98 Million | -9.94 Million | -30.97 Million | -23.65 Million |
| Common Stock Issuance | 5.81 Million | 4.38 Million | 16.22 Million | 23.22 Million | 8.41 Million | 9.32 Million |
| Other Financing Activities | -9.1 Million | 26.06 Million | -6.6 Million | 22.15 Million | 2.33 Million | 9.32 Million |
| Accounts receivables | -10.06 Million | -3.43 Million | -1.42 Million | -6.27 Million | -2.34 Million | -2.28 Million |
| Accounts payables | 5.77 Million | 4.75 Million | -3.59 Million | 3.16 Million | -735 Thousand | -389 Thousand |
| Inventory | 1.26 Million | 1.19 Million | 3.44 Million | -3.51 Million | -1.04 Million | -7.77 Million |
| Other working capital | 11.24 Million | 3.49 Million | 1.52 Million | 1.26 Million | -568 Thousand | 14.38 Million |
| Cash at beginning of period | 66.32 Million | 77.61 Million | 76.19 Million | 31.26 Million | 41.62 Million | 31.06 Million |
| Cash at end of period | 135.55 Million | 66.32 Million | 77.61 Million | 76.19 Million | 31.26 Million | 41.62 Million |
| Capital Expenditure | -139 Thousand | -413 Thousand | -469 Thousand | -1.23 Million | -1.08 Million | -298 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 69.22 Million | -11.28 Million | 1.42 Million | 44.92 Million | -10.35 Million | 10.56 Million |
| Free Cash Flow | 126.9 Million | 119.91 Million | 167.42 Million | 150.73 Million | 135.02 Million | 115.36 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 47.21 Million | 35.12 Million | 27.51 Million | 106.14 Million | 31.35 Million | 31.37 Million |
| Depreciation & Amortization | 499 Thousand | 257 Thousand | 120 Thousand | 2.36 Million | 630 Thousand | 169 Thousand |
| Deferred income taxes | -15.2 Million | -13.96 Million | -7.16 Million | -29.49 Million | -3.67 Million | -8.85 Million |
| Stock-based compensation | 16.1 Million | 15.2 Million | 13.24 Million | 48.94 Million | 13.06 Million | 12.87 Million |
| Change in working capital | 28.08 Million | 7.27 Million | -7.41 Million | 8.21 Million | -32.29 Million | 20.09 Million |
| Other non-cash items | -2.86 Million | 418 Thousand | 21.21 Million | -9.12 Million | -3.19 Million | -2.75 Million |
| Investing Cash Flow | -44.03 Million | -60.19 Million | -9.01 Million | 90.9 Million | 17.09 Million | -109.57 Million |
| Investments in PPE | -1.63 Million | -416 Thousand | - | -139 Thousand | - | -37 Thousand |
| Acquisitions | - | - | - | -91.04 Million | - | 109.53 Million |
| Investment purchases | -223.13 Million | -142.72 Million | -77.87 Million | -328.74 Million | -29.9 Million | -210.03 Million |
| Sales/Maturities of investments | 180.73 Million | 82.95 Million | 68.86 Million | 419.79 Million | 47 Million | 100.49 Million |
| Other Investing Activities | - | -59.77 Million | -9.01 Million | 91.04 Million | 17.09 Million | -109.53 Million |
| Financing Cash Flow | -21.09 Million | -2.15 Million | -543 Thousand | -148.72 Million | 766 Thousand | -3.91 Million |
| Debt repayment | - | - | - | - | -1.21 Million | -72 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -11.71 Million | -3.47 Million | -476 Thousand | -145.42 Million | -145.42 Million | -5.05 Million |
| Common Stock Issuance | -4.92 Million | 3.23 Million | 1.68 Million | 5.81 Million | 4.4 Million | 1.14 Million |
| Other Financing Activities | -21.09 Million | -1.9 Million | -1.75 Million | -9.1 Million | 144.22 Million | 5.2 Million |
| Accounts receivables | -5.88 Million | 7.68 Million | -6.39 Million | -10.06 Million | -6.49 Million | -2.07 Million |
| Accounts payables | -113 Thousand | 6.59 Million | -4.86 Million | 5.77 Million | 995 Thousand | 8.58 Million |
| Inventory | 1.08 Million | -1.68 Million | 983 Thousand | 1.26 Million | 329 Thousand | -544 Thousand |
| Other working capital | 33 Million | -5.31 Million | 2.86 Million | 11.24 Million | -27.12 Million | 14.12 Million |
| Cash at beginning of period | 128.58 Million | 149.75 Million | 135.55 Million | 66.32 Million | 111.8 Million | 172.37 Million |
| Cash at end of period | 137.28 Million | 128.58 Million | 149.75 Million | 135.55 Million | 135.55 Million | 111.8 Million |
| Capital Expenditure | -1.63 Million | -416 Thousand | - | -139 Thousand | - | -37 Thousand |
| Effect of forex changes on cash | - | - | - | - | -91.86 Million | 91.86 Million |
| Net cash flow / Change in cash | 8.7 Million | -21.16 Million | 14.19 Million | 69.22 Million | 23.75 Million | -60.57 Million |
| Free Cash Flow | 72.19 Million | 40.76 Million | 23.75 Million | 126.9 Million | 5.88 Million | 52.87 Million |
VIKASPROP
3022
6515
GENUSPRIME
8480
0RTK